Except for endoglin, which is used to highlight activated tumor BVs in renal cell carcinomas (in conjunction or not with other common endothelial markers) [18,19,20], there is sporadic data on B7-H3 [21] or endocan [22] expression in newly formed blood vessels from renal cell carcinomas, but there is no validated data on their use as therapeutic targets. The gene discussed is CD276; the disease is hereditary clear cell renal cell carcinoma.